111 related articles for article (PubMed ID: 21905526)
21. Impact of health care reform on medicare and dual medicare-medicaid beneficiaries.
Thorpe KE; Philyaw M
Cancer J; 2010; 16(6):584-7. PubMed ID: 21131789
[TBL] [Abstract][Full Text] [Related]
22. From the 2008 presidential campaign: candidates' health care plans.
J Med Assoc Ga; 2008; 97(3):10-3. PubMed ID: 19044078
[No Abstract] [Full Text] [Related]
23. Considering changes to CMS's national coverage decision process: applying lessons learned from FDA as a regulator of access to healthcare technology.
Zalesky CD
Food Drug Law J; 2002; 57(1):73-93. PubMed ID: 12118482
[No Abstract] [Full Text] [Related]
24. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
25. Drug distribution and expenditure: the issue of epoetin in Italy.
La Vecchia C; Franceschi S; Apolone G
Eur J Public Health; 2003 Dec; 13(4):367. PubMed ID: 14703326
[No Abstract] [Full Text] [Related]
26. Conditions for coverage fail to relieve administrative burden.
Wish D
Nephrol News Issues; 2005 Sep; 19(10):46-7, 51. PubMed ID: 16187648
[No Abstract] [Full Text] [Related]
27. Cost of treating predialysis patients with recombinant human erythropoietin.
Durand-Zaleski I; Goldfarb B; Blum-Boisgard C; Drüeke T; Kreis H
Nephrol Dial Transplant; 1993; 8(4):311-4. PubMed ID: 8390004
[TBL] [Abstract][Full Text] [Related]
28. The female face of Medicare. Cost-cutting without reform would harm the two-thirds of beneficiaries who are female.
Butler RN
Geriatrics; 1995 Oct; 50(10):10, 14. PubMed ID: 7557487
[No Abstract] [Full Text] [Related]
29. Eating an elephant. A sampling of the plateful of proposals in the Senate health care reform bill.
Meyer CR
Minn Med; 2010 Feb; 93(2):31-3. PubMed ID: 20302234
[No Abstract] [Full Text] [Related]
30. The drug add-on component--have all provider types seen budget neutrality?
Mentz K
Nephrol News Issues; 2005 Sep; 19(10):42-4. PubMed ID: 16187646
[No Abstract] [Full Text] [Related]
31. Economic considerations in a changing anemia environment.
Pizzi LT
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
[TBL] [Abstract][Full Text] [Related]
32. Drug usage evaluation of epoetin in chronic renal failure.
Mason NA; Iacobellis DP
Hosp Formul; 1992 Sep; 27(9):928-32, 937-8. PubMed ID: 10121421
[TBL] [Abstract][Full Text] [Related]
33. What happens to Medicare and Medicaid under the Clinton reform plan?
Thiel DK; White CL
Healthspan; 1993 Nov; 10(10):15-20. PubMed ID: 10130835
[No Abstract] [Full Text] [Related]
34. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients.
Nyvad O; Danielsen H; Madsen S
Lancet; 1994 Nov; 344(8932):1305-6. PubMed ID: 7968018
[No Abstract] [Full Text] [Related]
35. [Erythropoietin in renal anemia].
Peña Amaro MP; García López J; Camacho Romera M
Rev Enferm; 1992 Mar; 15(163):67-70. PubMed ID: 1565973
[No Abstract] [Full Text] [Related]
36. Universal health insurance coverage or economic relief--a false choice.
Gruber J
N Engl J Med; 2009 Jan; 360(5):437-9. PubMed ID: 19179311
[No Abstract] [Full Text] [Related]
37. The need for health care reform.
Mossinghoff GJ
Health Syst Rev; 1994; 27(3):5-6. PubMed ID: 10134516
[No Abstract] [Full Text] [Related]
38. EPO--one year later. Fighting anemia in the courtroom.
Riley JB; Pristave RJ
Nephrol News Issues; 1990 May; 4(5):27. PubMed ID: 2348877
[No Abstract] [Full Text] [Related]
39. Insurance woes threaten gift of life.
Harris P
Nephrol News Issues; 2008 Aug; 22(9):48-9. PubMed ID: 18778007
[No Abstract] [Full Text] [Related]
40. Payment reform: it's time to get real!
Susman J
J Fam Pract; 2011 Oct; 60(10):572. PubMed ID: 21977483
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
